Capreomycin

Summary

Capreomycin (CHEMBL2221250) is an approved protein (ATC J04AB30); indicated across 2 conditions including tuberculosis and osteomyelitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: J04AB30
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 1321.4 Da · C50H88N28O15

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2221250
Name	Capreomycin
Type	Protein
Max phase	4
FDA approved	no
PubChem CID	73952296
ATC	J04AB30
Molecular formula	C50H88N28O15
Molecular weight	1321.4
InChIKey	VCOPTHOUUNAYKQ-DAOVIKHBSA-N

SMILES: C[C@H]1C(=O)N[C@H](C(=O)N/C(=C\NC(=O)N)/C(=O)N[C@H](C(=O)NC[C@@H](C(=O)N1)N)C2CCN=C(N2)N)CNC(=O)CC(CCCN)N.C1CN=C(NC1[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C\NC(=O)N)/C(=O)N2)CNC(=O)CC(CCCN)N)CO)N)N

IUPAC name: 3,6-diamino-N-[[(2S,5S,8Z,11S,15S)-15-amino-11-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;3,6-diamino-N-[[(2S,5S,8Z,11S,15S)-15-amino-11-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide

Also known as: Capastat, Capostatin, Capreomicin, Capreomicina, Capreomycin, Capreomycine, Capromycin, capreomycin, CAPREOMYCINE, CAPREOMYCIN

Parent form; salt/anhydrous children: CHEMBL2218913

Patent coverage: 27 distinct patent families (36 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
tuberculosis	4	MONDO:0018076	MONDO:0018076
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00042289	Not specified	COMPLETED	Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).